1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tong Ren Tang Technologies Co., Ltd. Class H

Tong Ren Tang Technologies Co., Ltd. Class H

0.40
USD
-0.10
(-19.35%)
634.39MMarket Cap
Mar 19Next Earn
Tong Ren Tang Technologies Co., Ltd. Class H
OTC:TGRNF
(OTC Markets)

Recent

price

0.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.34
1.65
2.07
2.41
2.61
3.18
3.64
3.92
3.95
3.5
3.6
4.22
4.68
5.29
5.67
5.06
- -
Revenue per Share
0.17
0.22
0.28
0.32
0.36
0.42
0.47
0.52
0.53
0.33
0.37
0.4
0.46
0.46
0.41
0.31
- -
Basic EPS, GAAP
0.18
0.08
0.24
0.15
0.04
0.1
-0.02
0.2
0.48
0.61
-0.26
0.68
0.44
0.35
-0.12
1.13
- -
Free Cash Flow per Basic Share
0.08
0.08
0.1
0.12
0.13
0.14
0.15
0.16
0.17
0.18
0.16
0.16
0.16
0.16
0.18
0.18
- -
Dividend per Share
1.33
1.46
1.65
2.54
2.77
3.1
3.44
3.76
4.15
4.32
4.48
4.67
5.06
5.38
5.63
5.73
5.7
Book Value per Share
1.29
1.34
1.65
2.54
2.77
3.05
3.37
3.7
4.09
4.26
4.43
4.62
5.01
5.33
5.57
5.67
5.65
Tangible Book Value per Share
1,176
1,176
1,176
1,209
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
1,281
Basic Weighted Avg Shares
1,579
1,936
2,439
2,911
3,341
4,067
4,665
5,025
5,060
4,476
4,607
5,400
5,992
6,773
7,260
6,484
- -
Sales/Revenue/Turnover
16.61
18.1
19.94
21.13
21.3
21.68
21.59
23.21
23.66
20.96
20.96
19.9
20.03
16.73
13.57
12.37
- -
Operating Margin (%)
43
41
43
47
61
75
79
85
88
160
270
250
262
277
290
334
- -
Depreciation Expense
198
255
330
390
462
541
596
667
678
418
468
507
583
590
522
396
- -
Net Income, GAAP
15.77
16.21
16.84
15.45
16.78
17.47
16.86
16.83
16.67
19.72
16.3
17.05
17.36
14.64
16.42
19.67
- -
Effective Tax Rate (%)
12.54
13.15
13.54
13.4
13.83
13.3
12.77
13.27
13.4
9.33
10.15
9.39
9.73
8.71
7.19
6.11
- -
Profit Margin (%)
1,291
1,384
1,589
3,291
3,415
3,912
5,172
5,442
5,899
5,891
4,999
5,672
7,021
7,820
7,992
8,411
7,935
Working Capital
- -
- -
- -
39
- -
- -
918
915
911
1,283
578
819
1,296
1,476
1,283
1,545
1,241
LT Debt
1,740
1,942
2,227
4,009
4,436
5,163
5,885
6,460
7,277
7,415
7,752
8,158
9,017
9,652
10,165
10,265
10,051
Total Equity
13.14
14.59
17.95
15.63
13.53
14.64
13.45
13.22
12.35
8.45
8.54
9.24
9.67
8.59
6.85
5.14
- -
Return on Invested Capital (%)
10.13
12.11
12.1
8.71
7.12
6.92
5.66
5.23
4.54
1.47
2.09
2.07
2.04
2.1
1.76
1.44
- -
Return on Capital (%)
13.03
15.51
18.05
15.02
13.58
14.39
14.23
14.46
13.38
7.7
8.31
8.66
9.35
8.83
7.4
5.45
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
480
460
670
LT Borrowings
1,842
1,453
1,102
LT Finance Leases
93
91
139
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,281
1,281
1,281
Market Capitalization
5,750
6,435
4,304

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
10,996
10,192
9,882
Cash, Cash Equivalents & STI
5,147
4,834
5,005
Accounts Receivable, Net
1,061
670
1,014
Inventories
4,631
4,547
3,763
Total Current Liabilities
2,282
1,781
1,947
Payables & Accruals
- -
- -
- -
ST Debt
480
460
670
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.19%
5.82%
0.98%
Free Cash Flow
-273.07%
-312.62%
-1,011.73%
Net Income, GAAP
-1.37%
-2.2%
-24.06%
Sales/Revenue/Turnover
5.22%
7.54%
-10.69%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
7,260
2025
- -
- -
6,484
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.41
2025
- -
- -
0.31
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.18
2025
- -
- -
0.18
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tong Ren Tang Technologies Co. Ltd. (1666.HK) manufactures and sells traditional Chinese medicine products in Mainland China and Hong Kong. The company, founded in 1669 and headquartered in Beijing, operates through segments including the Company, Tong Ren Tang Chinese Medicine, and Others; it develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products; and produces ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, cosmetics, granules, pills, decoction pieces, Chinese herbal remedies, health supplements, and topical medicines. It also provides medical research and development, advertisement, Chinese medical consultations and treatments, internal and external surgery, medical examinations, traditional Chinese medicine department and hospital management activities, biochemical product processing, plant extraction and processing, and medical services. In addition, the company engages in technological development and sale of biological products, Chinese and Western medicines, cosmetics, and healthcare products. Recent developments include entering into a supplemental trademark framework agreement with Tong Ren Tang Holdings on November 28, 2025, revising the scope of subsidiaries subject to licence fees and annual caps under the current trademark licence agreement for the years ending 2026 and 2027; renewing its Land Use Right Leasing Agreement with Tong Ren Tang Holdings; and in January 2024, entering an equity transfer agreement with Beijing Tong Ren Tang Healthcare Investment Co., Ltd. The company employs approximately 3,991 people and focuses on the healthcare sector, particularly drug manufacturing-general, with a subsidiary relationship to Beijing Tong Ren Tang Chinese Medicine (Hong Kong) Group Co. Ltd.